$214 Million is the total value of DAFNA Capital Management LLC's 75 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BVXV | Exit | BIONDVAX PHARMACEUTICALS LTDspond ads | $0 | – | -3,399 | -100.0% | -0.01% | – |
| CLSD | Exit | CLEARSIDE BIOMEDICAL INC | $0 | – | -5,000 | -100.0% | -0.03% | – |
| UMRX | Exit | UNUM THERAPEUTICS INC | $0 | – | -7,900 | -100.0% | -0.04% | – |
| RCUS | Exit | ARCUS BIOSCIENCES INC | $0 | – | -7,500 | -100.0% | -0.06% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -79,969 | -100.0% | -0.08% | – |
| Exit | DEXCOM INCdbcv 0.750% 5/1 | $0 | – | -250,000 | -100.0% | -0.12% | – | |
| TNDM | Exit | TANDEM DIABETES CARE INC | $0 | – | -60,000 | -100.0% | -0.14% | – |
| SPRO | Exit | SPERO THERAPEUTICS INC | $0 | – | -29,544 | -100.0% | -0.20% | – |
| Exit | INOTEK PHARMACEUTICALS CORPnote 5.750% 8/0 | $0 | – | -600,000 | -100.0% | -0.28% | – | |
| GEMP | Exit | GEMPHIRE THERAPEUTICS INC | $0 | – | -100,000 | -100.0% | -0.32% | – |
| Exit | IRONWOOD PHARMACEUTICALS INCdbcv 2.250% 6/1 | $0 | – | -573,000 | -100.0% | -0.33% | – | |
| SCPH | Exit | SCPHARMACEUTICALS INC | $0 | – | -55,844 | -100.0% | -0.34% | – |
| Exit | DERMIRA INCnote 3.000% 5/1 | $0 | – | -1,500,000 | -100.0% | -0.58% | – | |
| CGNT | Exit | COGENTIX MEDICAL INC | $0 | – | -310,382 | -100.0% | -0.58% | – |
| PTI | Exit | PROTEOSTASIS THERAPEUTICS IN | $0 | – | -267,100 | -100.0% | -0.62% | – |
| AQXP | Exit | AQUINOX PHARMACEUTICALS INC | $0 | – | -107,928 | -100.0% | -0.74% | – |
| CMTA | Exit | CLEMENTIA PHARMACEUTICALS IN | $0 | – | -105,000 | -100.0% | -0.77% | – |
| PODD | Exit | INSULET CORP | $0 | – | -32,484 | -100.0% | -1.37% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.